Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Jarrard

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
European Urology Oncology|April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trialDaniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Cancers|January 28, 2026
Percutaneous Microwave Ablation Preserves Renal Function with Similar Long Term Oncologic Outcomes Compared to Surgery for Clinical T1 Renal Cell CarcinomaDaniel F Roadman, Daniel D Shapiro, Arighno Das, et al.
Urology|October 5, 2019
Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or SurgeryDaniel D Shapiro, Shane A Wells, Sara L Best, et al.
The Prostate|May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
The New England Journal of Medicine|August 6, 2015
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J Sweeney, Yu-Hui Chen, Michael Carducci, et al.
Neoplasia (New York, N.Y.)|February 20, 2026
Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancerTanaya A Purohit, Joseph Gawdzik, Eric A Armstrong, et al.
Journal of Medical Imaging (Bellingham, Wash.)|October 16, 2020
Accurate segmentation of prostate cancer histomorphometric features using a weakly supervised convolutional neural networkJohn D Bukowy, Halle Foss, Sean D McGarry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 8, 2011
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917James R Marshall, Catherine M Tangen, Wael A Sakr, et al.
Urology|December 13, 2025
Outcomes of Patients With Localized Renal Cell Carcinoma on Immunosuppression Following Solid Organ TransplantationParth V Shah, Edwin Jason Abel, Joshua D Mezrich, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
European Urology Oncology|April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trialDaniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Cancers|January 28, 2026
Percutaneous Microwave Ablation Preserves Renal Function with Similar Long Term Oncologic Outcomes Compared to Surgery for Clinical T1 Renal Cell CarcinomaDaniel F Roadman, Daniel D Shapiro, Arighno Das, et al.
Urology|October 5, 2019
Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or SurgeryDaniel D Shapiro, Shane A Wells, Sara L Best, et al.
The Prostate|May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
The New England Journal of Medicine|August 6, 2015
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J Sweeney, Yu-Hui Chen, Michael Carducci, et al.
Neoplasia (New York, N.Y.)|February 20, 2026
Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancerTanaya A Purohit, Joseph Gawdzik, Eric A Armstrong, et al.
Journal of Medical Imaging (Bellingham, Wash.)|October 16, 2020
Accurate segmentation of prostate cancer histomorphometric features using a weakly supervised convolutional neural networkJohn D Bukowy, Halle Foss, Sean D McGarry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 8, 2011
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917James R Marshall, Catherine M Tangen, Wael A Sakr, et al.
Urology|December 13, 2025
Outcomes of Patients With Localized Renal Cell Carcinoma on Immunosuppression Following Solid Organ TransplantationParth V Shah, Edwin Jason Abel, Joshua D Mezrich, et al.
Pageof 14